• Home
  • Search Results
  • Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research (2015-02-18)
Nicolas A Giraldo, Etienne Becht, Franck Pagès, Georgios Skliris, Virginie Verkarre, Yann Vano, Arnaud Mejean, Nicolas Saint-Aubert, Laetitia Lacroix, Ivo Natario, Audrey Lupo, Marco Alifano, Diane Damotte, Aurelie Cazes, Frederic Triebel, Gordon J Freeman, Marie-Caroline Dieu-Nosjean, Stephane Oudard, Wolf H Fridman, Catherine Sautès-Fridman
ABSTRACT

Clear cell renal cell carcinoma (ccRCC) has shown durable responses to checkpoint blockade therapies. However, important gaps persist in the understanding of its immune microenvironment. This study aims to investigate the expression and prognostic significance of immune checkpoints in primary and metastatic ccRCC, in relation with mature dendritic cells (DC) and T-cell densities. We investigated the infiltration and the localization of CD8(+) T cells and mature DC, and the expression of immune checkpoints (PD-1, LAG-3, PD-L1, and PD-L2) in relation with prognosis, in 135 primary ccRCC tumors and 51 ccRCC lung metastases. RNA expression data for 496 primary ccRCC samples were used as confirmatory cohort. We identify two groups of tumors with extensive CD8(+) T-cell infiltrates. One group, characterized by high expression of immune checkpoints in the absence of fully functional mature DC, is associated with increased risk of disease progression. The second group, characterized by low expression of immune checkpoints and localization of mature DC in peritumoral immune aggregates (tertiary lymphoid structures), is associated with good prognosis. The expression of the immune checkpoints and the localization of DC in the tumor microenvironment modulate the clinical impact of CD8(+) T cells in ccRCC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Trimesic acid, 95%
Sigma-Aldrich
Trimethylaluminum, 97%
Sigma-Aldrich
Phosphatase substrate, 5 mg tablets
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, suitable for enzyme immunoassay, ≥99.0% (enzymatic)
Sigma-Aldrich
Trimethylaluminum solution, 2.0 M in toluene
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, tablet
Sigma-Aldrich
Phosphatase substrate, powder
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, tablet
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
Trimethylaluminum solution, 2.0 M in hexanes
Sigma-Aldrich
3-Amino-9-ethylcarbazole, tablet
Sigma-Aldrich
3-Amino-9-ethylcarbazole, ≥95% (HPLC), powder
Sigma-Aldrich
Trimethylaluminum, packaged for use in deposition systems
Sigma-Aldrich
4-Nitrophenyl phosphate disodium salt hexahydrate, tablet
Sigma-Aldrich
Phosphatase substrate, 40 mg tablets
Sigma-Aldrich
Phosphatase substrate, 100 mg capsules
Sigma-Aldrich
Trimethylaluminum solution, 2.0 M in heptane
Sigma-Aldrich
Phosphatase substrate, Suitable for manufacturing of diagnostic kits and reagents
Sigma-Aldrich
Phosphatase substrate, 40 mg capsules